Identification

Name
Metoprolol
Accession Number
DB00264  (APRD00208)
Type
Small Molecule
Groups
Approved, Investigational
Description

Metoprolol is a cardioselective β1-adrenergic blocking agent used for acute myocardial infarction (MI), heart failure, angina pectoris and mild to moderate hypertension. It may also be used for supraventricular and tachyarrhythmias and prophylaxis for migraine headaches. Metoprolol is structurally similar to bisoprolol, acebutolol and atenolol in that it has two substituents in the para position of the benzene ring. The β1-selectivity of these agents is thought to be due in part to the large substituents in the para position. At low doses, metoprolol selectively blocks cardiac β1-adrenergic receptors with little activity against β2-adrenergic receptors of the lungs and vascular smooth muscle. Receptor selectivity decreases with higher doses. Unlike propranolol and pindolol, metoprolol does not exhibit membrane-stabilizing or intrinsic sympathomimetic activity. Membrane-stabilizing effects are only observed at doses much higher than those needed for β-adrenergic blocking activity. Metoprolol possesses a single chiral centre and is administered as a racemic mixture.

Structure
Thumb
Synonyms
  • (RS)-Metoprolol
  • 1-(isopropylamino)-3-[4-(2-methoxyethyl)phenoxy]propan-2-ol
  • DL-metoprolol
External IDs
CGP-2175
Product Ingredients
IngredientUNIICASInChI Key
Metoprolol fumarateIO1C09Z674119637-66-0BRIPGNJWPCKDQZ-WXXKFALUSA-N
Metoprolol succinateTH25PD4CCB98418-47-4RGHAZVBIOOEVQX-UHFFFAOYSA-N
Metoprolol tartrateW5S57Y3A5L56392-17-7YGULWPYYGQCFMP-CEAXSRTFSA-N
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ava-metoprololTablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-metoprololTablet100 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-metoprolol (type L)Tablet100 mgOralAvanstra Inc2011-10-112014-08-21Canada
Ava-metoprolol (type L)Tablet50 mgOralAvanstra Inc2011-10-112014-08-21Canada
Betaloc Durules Tab 200 mgTablet, extended release200 mgOralAstra Zeneca1980-12-312009-12-15Canada
Betaloc IV Inj 1 mg/mlSolution1 mgIntravenousAstra Zeneca1987-12-312016-05-12Canada
Betaloc Tab 100 mgTablet100 mgOralAstra Zeneca1977-12-312009-12-15Canada
Betaloc Tab 50 mgTablet50 mgOralAstra Zeneca1978-12-312009-12-15Canada
Co Metoprolol-L Tablets 100mgTablet100 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Co Metoprolol-L Tablets 50mgTablet50 mgOralCobalt LaboratoriesNot applicableNot applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo Metoprolol (type L) Tab 50mgTablet50 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo Metoprolol Tab 100mgTablet100 mgOralApotex Corporation1984-12-31Not applicableCanada
Apo Metoprolol Tab 50mgTablet50 mgOralApotex Corporation1984-12-31Not applicableCanada
Apo-metoprololTablet25 mgOralApotex Corporation2002-10-08Not applicableCanada
Apo-metoprolol (type L) Tab 100mgTablet100 mgOralApotex Corporation1988-12-31Not applicableCanada
Apo-metoprolol SRTablet, extended release100 mgOralApotex Corporation2007-07-30Not applicableCanada
Apo-metoprolol SRTablet, extended release200 mgOralApotex Corporation2007-07-30Not applicableCanada
MetoprololInjection, solution5 mg/5mLIntravenousFresenius Kabi2010-10-28Not applicableUs
MetoprololInjection5 mg/5mLIntravenousCardinal Health2012-09-25Not applicableUs
MetoprololInjection, solution1 mg/mLIntravenousSagent Pharmaceuticals2010-05-10Not applicableUs
Unapproved/Other Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Metoprolol Succinate E/rTablet, extended release50 mg/1OralDirectrx2017-11-10Not applicableUs
Metoprolol TartrateInjection, solution5 mg/5mLIntravenousAlvogen, Inc.2017-11-02Not applicableUs
International/Other Brands
Corvitol / Minax / Selokeen / TOPROL / Toprol-XL / TOPROLXL
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
DutoprolMetoprolol succinate (25 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2011-09-162016-11-03Us
DutoprolMetoprolol succinate (25 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralConcordia Pharmaceuticals, Inc2014-07-01Not applicableUs
DutoprolMetoprolol succinate (100 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralCovis Pharmaceuticals, Inc.2014-07-012017-02-28Us
DutoprolMetoprolol succinate (100 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2011-12-30Not applicableUs
DutoprolMetoprolol succinate (50 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2011-09-162016-11-03Us
DutoprolMetoprolol succinate (50 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralConcordia Pharmaceuticals, Inc2014-07-01Not applicableUs
DutoprolMetoprolol succinate (25 mg/1) + Hydrochlorothiazide (12.5 mg/1)TabletOralCovis Pharmaceuticals, Inc.2014-07-012017-01-31Us
DutoprolMetoprolol succinate (25 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2011-12-302017-04-30Us
DutoprolMetoprolol succinate (50 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2011-12-302017-11-30Us
DutoprolMetoprolol succinate (100 mg/1) + Hydrochlorothiazide (12.5 mg/1)Tablet, film coatedOralAstra Zeneca Lp2011-09-162016-11-03Us
Categories
UNII
GEB06NHM23
CAS number
51384-51-1
Weight
Average: 267.3639
Monoisotopic: 267.183443671
Chemical Formula
C15H25NO3
InChI Key
IUBSYMUCCVWXPE-UHFFFAOYSA-N
InChI
InChI=1S/C15H25NO3/c1-12(2)16-10-14(17)11-19-15-6-4-13(5-7-15)8-9-18-3/h4-7,12,14,16-17H,8-11H2,1-3H3
IUPAC Name
1-[4-(2-methoxyethyl)phenoxy]-3-[(propan-2-yl)amino]propan-2-ol
SMILES
COCCC1=CC=C(OCC(O)CNC(C)C)C=C1

Pharmacology

Indication

For the management of acute myocardial infarction, angina pectoris, heart failure and mild to moderate hypertension. May be used to treat supraventricular and tachyarrhythmias and as prophylaxis for migraine headaches.

Structured Indications
Pharmacodynamics

Metoprolol, a competitive, beta1-selective (cardioselective) adrenergic antagonist, is similar to atenolol in its moderate lipid solubility, lack of intrinsic sympathomimetic activity (ISA), and weak membrane stabilizing activity (MSA).

Mechanism of action

Metoprolol competes with adrenergic neurotransmitters such as catecholamines for binding at beta(1)-adrenergic receptors in the heart. Beta(1)-receptor blockade results in a decrease in heart rate, cardiac output, and blood pressure.

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
UBeta-2 adrenergic receptor
antagonist
Human
Absorption

Rapid and complete, 50%

Volume of distribution
Not Available
Protein binding

12%

Metabolism

Primarily hepatic

Route of elimination

Less than 5% of an oral dose of metoprolol is recovered unchanged in the urine; the rest is excreted by the kidneys as metabolites that appear to have no beta-blocking activity.

Half life

3-7 hours

Clearance
Not Available
Toxicity

LD50=5500 mg/kg (orally in rats), toxic effects include bradycardia, hypotension, bronchospasm, and cardiac failure. LD50=2090 mg/kg (orally in mice)

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Metoprolol Action PathwayDrug action
Pharmacogenomic Effects/ADRs
Interacting Gene/EnzymeAllele nameGenotype(s)Defining Change(s)Type(s)DescriptionDetails
Beta-1 adrenergic receptor---(A;A)A AlleleEffect Directly StudiedPatients with this genotype have a greater reduction in blood pressure with metoprolol.Details
Cytochrome P450 2D6CYP2D6*4(A;A)A alleleDirectly Studied EffectPatients with this genotype have reduced metabolism of metoprolol.Details
Beta-1 adrenergic receptor---(C;C) / (C;G)G > CEffect Directly StudiedPatients with this genotype have a greater reduction in blood pressure with metoprolol.Details
Cytochrome P450 2D6CYP2D6*3Not AvailableC alleleADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*5Not AvailableWhole-gene deletionADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*6Not Available1707delTADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*7Not Available2935A>CADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*8Not Available1758G>TADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*11Not Available883G>CADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*12Not Available124G>AADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*13Not AvailableCYP2D7/2D6 hybrid gene structureADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*14ANot Available1758G>AADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*15Not Available137insT, 137_138insTADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*19Not Available2539_2542delAACTADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*20Not Available1973_1974insGADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*21Not Available2573insCADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*31Not Available-1770G>A / -1584C>G  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*36Not Available100C>T / -1426C>T  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*38Not Available2587_2590delGACTADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*40Not Available1863_1864ins(TTT CGC CCC)2ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*42Not Available3259_3260insGTADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*44Not Available2950G>CADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*47Not Available100C>T / -1426C>T  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*51Not Available-1584C>G / -1235A>G  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*56Not Available3201C>TADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*57Not Available100C>T / 310G>T  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*62Not Available4044C>TADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*68ANot Available-1426C>T / -1235A>G  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*68BNot AvailableSimilar but not identical switch region compared to CYP2D6*68A. Found in tandem arrangement with CYP2D6*4.ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*69Not Available2988G>A / -1426C>T  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*92Not Available1995delCADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*100Not Available-1426C>T / -1235A>G  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details
Cytochrome P450 2D6CYP2D6*101Not Available-1426C>T / -1235A>G  … show all ADR InferredIncreased risk of slow heart rate (bradycardia)Details

Interactions

Drug Interactions
DrugInteractionDrug group
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Metoprolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Experimental, Illicit
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the hypotensive activities of Metoprolol.Experimental
AbirateroneThe serum concentration of Metoprolol can be increased when it is combined with Abiraterone.Approved
AcebutololThe serum concentration of Metoprolol can be increased when it is combined with Acebutolol.Approved
AceclofenacAceclofenac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Metoprolol.Approved
AcepromazineAcepromazine may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Metoprolol.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Metoprolol.Approved
AcetohexamideMetoprolol may increase the hypoglycemic activities of Acetohexamide.Investigational, Withdrawn
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Metoprolol.Approved
AcetyldigitoxinMetoprolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinMetoprolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Metoprolol.Approved
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Metoprolol.Approved
AgmatineAgmatine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Experimental, Investigational
AjmalineThe serum concentration of Metoprolol can be increased when it is combined with Ajmaline.Approved, Investigational
AlaproclateThe serum concentration of Metoprolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Metoprolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Metoprolol.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Metoprolol.Approved, Illicit
AlfuzosinAlfuzosin may increase the hypotensive activities of Metoprolol.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Metoprolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Metoprolol.Experimental
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Metoprolol.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Metoprolol.Approved
AlprenololThe metabolism of Alprenolol can be decreased when combined with Metoprolol.Approved, Withdrawn
AmbenoniumAmbenonium may increase the bradycardic activities of Metoprolol.Approved
AmbrisentanMetoprolol may increase the hypotensive activities of Ambrisentan.Approved, Investigational
Ambroxol acefyllinateMetoprolol may decrease the bronchodilatory activities of Ambroxol acefyllinate.Experimental, Investigational
AmifostineMetoprolol may increase the hypotensive activities of Amifostine.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Amiloride.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Metoprolol.Approved, Withdrawn
AminophyllineMetoprolol may decrease the bronchodilatory activities of Aminophylline.Approved
AmiodaroneThe serum concentration of Metoprolol can be increased when it is combined with Amiodarone.Approved, Investigational
AmitriptylineThe serum concentration of Metoprolol can be increased when it is combined with Amitriptyline.Approved
AmlodipineThe serum concentration of Metoprolol can be increased when it is combined with Amlodipine.Approved
AmobarbitalAmobarbital may increase the hypotensive activities of Metoprolol.Approved, Illicit
AmodiaquineThe serum concentration of Metoprolol can be increased when it is combined with Amodiaquine.Approved, Investigational
AmoxapineThe metabolism of Amoxapine can be decreased when combined with Metoprolol.Approved
AmphetamineThe serum concentration of Metoprolol can be increased when it is combined with Amphetamine.Approved, Illicit
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Metoprolol.Approved, Investigational
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Metoprolol.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Metoprolol.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Metoprolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Metoprolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Metoprolol.Investigational
AntipyrineThe serum concentration of Metoprolol can be increased when it is combined with Antipyrine.Approved
ApocyninApocynin may decrease the antihypertensive activities of Metoprolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Metoprolol.Approved
ArbutamineMetoprolol may decrease the bronchodilatory activities of Arbutamine.Approved
ArecolineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Arecoline.Experimental
ArformoterolThe metabolism of Arformoterol can be decreased when combined with Metoprolol.Approved, Investigational
AripiprazoleThe serum concentration of Metoprolol can be increased when it is combined with Aripiprazole.Approved, Investigational
ArmodafinilThe metabolism of Metoprolol can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metoprolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Metoprolol.Approved, Investigational
ArtemetherThe serum concentration of Metoprolol can be increased when it is combined with Artemether.Approved
AsenapineThe serum concentration of Metoprolol can be increased when it is combined with Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Metoprolol.Approved, Withdrawn
AtenololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Atenolol.Approved
AtomoxetineThe serum concentration of Metoprolol can be increased when it is combined with Atomoxetine.Approved
AtorvastatinThe serum concentration of Metoprolol can be increased when it is combined with Atorvastatin.Approved
AvanafilAvanafil may increase the antihypertensive activities of Metoprolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Metoprolol.Withdrawn
AzelastineThe serum concentration of Metoprolol can be increased when it is combined with Azelastine.Approved
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Azilsartan medoxomil.Approved
BalsalazideBalsalazide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
BambuterolMetoprolol may decrease the bronchodilatory activities of Bambuterol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Metoprolol.Experimental
BarbitalBarbital may increase the hypotensive activities of Metoprolol.Illicit
BarnidipineThe risk or severity of adverse effects can be increased when Barnidipine is combined with Metoprolol.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Benazepril.Approved, Investigational
BendazacBendazac may decrease the antihypertensive activities of Metoprolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bendroflumethiazide.Approved
BenmoxinBenmoxin may increase the hypotensive activities of Metoprolol.Withdrawn
BenorilateBenorilate may decrease the antihypertensive activities of Metoprolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Metoprolol.Withdrawn
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Metoprolol.Approved
BenzphetamineBenzphetamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Metoprolol.Approved
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Metoprolol.Approved
BepridilThe risk or severity of adverse effects can be increased when Bepridil is combined with Metoprolol.Approved, Withdrawn
BeractantMetoprolol may increase the bradycardic activities of Beractant.Approved
BetaxololThe serum concentration of Metoprolol can be increased when it is combined with Betaxolol.Approved
BethanecholThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Metoprolol.Experimental
BicalutamideThe serum concentration of Metoprolol can be increased when it is combined with Bicalutamide.Approved
BietaserpineBietaserpine may increase the hypotensive activities of Metoprolol.Experimental
BimatoprostMetoprolol may increase the hypotensive activities of Bimatoprost.Approved, Investigational
BiperidenThe serum concentration of Metoprolol can be increased when it is combined with Biperiden.Approved, Investigational
BisoprololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Metoprolol.Investigational
BortezomibThe serum concentration of Metoprolol can be increased when it is combined with Bortezomib.Approved, Investigational
BosentanBosentan may increase the hypotensive activities of Metoprolol.Approved, Investigational
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Metoprolol.Approved
BQ-123Metoprolol may increase the hypotensive activities of BQ-123.Investigational
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Metoprolol.Approved
BretyliumBretylium may increase the bradycardic activities of Metoprolol.Approved
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Metoprolol.Approved
BrimonidineBrimonidine may increase the antihypertensive activities of Metoprolol.Approved
BrofaromineBrofaromine may increase the hypotensive activities of Metoprolol.Experimental
BromfenacBromfenac may decrease the antihypertensive activities of Metoprolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
BrompheniramineThe serum concentration of Metoprolol can be increased when it is combined with Brompheniramine.Approved
BucillamineBucillamine may decrease the antihypertensive activities of Metoprolol.Investigational
BucindololMetoprolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Metoprolol.Experimental
BufuralolThe metabolism of Bufuralol can be decreased when combined with Metoprolol.Experimental, Investigational
BumadizoneBumadizone may decrease the antihypertensive activities of Metoprolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Bumetanide.Approved
BunazosinMetoprolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Metoprolol.Approved, Investigational
BupranololMetoprolol may increase the hypotensive activities of Bupranolol.Approved
BuprenorphineThe serum concentration of Metoprolol can be increased when it is combined with Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe serum concentration of Metoprolol can be increased when it is combined with Bupropion.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Metoprolol.Approved, Investigational
CabergolineMetoprolol may increase the vasoconstricting activities of Cabergoline.Approved
CadralazineCadralazine may increase the hypotensive activities of Metoprolol.Experimental
CafedrineMetoprolol may increase the hypotensive activities of Cafedrine.Investigational
CaffeineThe metabolism of Caffeine can be decreased when combined with Metoprolol.Approved
CalfactantMetoprolol may increase the bradycardic activities of Calfactant.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Canagliflozin.Approved
CandesartanMetoprolol may increase the hypotensive activities of Candesartan.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Candesartan cilexetil.Approved
CandoxatrilMetoprolol may increase the hypotensive activities of Candoxatril.Experimental
CaptoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Captopril.Approved
CarbacholThe risk or severity of adverse effects can be increased when Metoprolol is combined with Carbachol.Approved
CarbamazepineThe metabolism of Metoprolol can be increased when combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Metoprolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Carbetocin is combined with Metoprolol.Approved
CarbinoxamineThe serum concentration of Metoprolol can be increased when it is combined with Carbinoxamine.Approved
CarbutamideMetoprolol may increase the hypoglycemic activities of Carbutamide.Experimental
CariprazineThe metabolism of Cariprazine can be decreased when combined with Metoprolol.Approved
CaroxazoneCaroxazone may increase the hypotensive activities of Metoprolol.Withdrawn
CarprofenCarprofen may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved, Withdrawn
CarteololThe serum concentration of Metoprolol can be increased when it is combined with Carteolol.Approved
CarvedilolMetoprolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Metoprolol.Experimental
CelecoxibThe serum concentration of Metoprolol can be increased when it is combined with Celecoxib.Approved, Investigational
CeliprololMetoprolol may decrease the bronchodilatory activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Metoprolol.Approved, Vet Approved
CeritinibMetoprolol may increase the bradycardic activities of Ceritinib.Approved
CerivastatinThe serum concentration of Metoprolol can be increased when it is combined with Cerivastatin.Withdrawn
CevimelineThe metabolism of Cevimeline can be decreased when combined with Metoprolol.Approved
ChloramphenicolThe metabolism of Metoprolol can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Metoprolol.Approved, Illicit
ChloroquineThe serum concentration of Metoprolol can be increased when it is combined with Chloroquine.Approved, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorphenamineThe serum concentration of Metoprolol can be increased when it is combined with Chlorphenamine.Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Metoprolol.Experimental
ChlorpromazineThe serum concentration of Metoprolol can be increased when it is combined with Chlorpromazine.Approved, Vet Approved
ChlorpropamideMetoprolol may increase the hypoglycemic activities of Chlorpropamide.Approved
ChlorthalidoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Chlorthalidone.Approved
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Metoprolol.Approved
CholecalciferolThe serum concentration of Metoprolol can be increased when it is combined with Cholecalciferol.Approved, Nutraceutical
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Metoprolol.Approved
CicletanineMetoprolol may increase the hypotensive activities of Cicletanine.Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of adverse effects can be increased when Cilnidipine is combined with Metoprolol.Approved, Investigational
CilostazolThe metabolism of Cilostazol can be decreased when combined with Metoprolol.Approved
CimetidineThe serum concentration of Metoprolol can be increased when it is combined with Cimetidine.Approved
CinacalcetThe serum concentration of Metoprolol can be increased when it is combined with Cinacalcet.Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Metoprolol.Approved, Investigational
CisaprideThe serum concentration of Metoprolol can be increased when it is combined with Cisapride.Approved, Investigational, Withdrawn
CitalopramThe serum concentration of Metoprolol can be increased when it is combined with Citalopram.Approved
ClemastineThe serum concentration of Metoprolol can be increased when it is combined with Clemastine.Approved
ClenbuterolMetoprolol may decrease the bronchodilatory activities of Clenbuterol.Approved, Investigational, Vet Approved
ClevidipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Clevidipine.Approved
ClobazamThe serum concentration of Metoprolol can be increased when it is combined with Clobazam.Approved, Illicit
ClofarabineThe risk or severity of adverse effects can be increased when Clofarabine is combined with Metoprolol.Approved, Investigational
ClomipramineThe serum concentration of Metoprolol can be increased when it is combined with Clomipramine.Approved, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Metoprolol.Approved
CloranololMetoprolol may increase the hypotensive activities of Cloranolol.Experimental
ClotrimazoleThe serum concentration of Metoprolol can be increased when it is combined with Clotrimazole.Approved, Vet Approved
ClozapineThe serum concentration of Metoprolol can be increased when it is combined with Clozapine.Approved
CobicistatThe serum concentration of Metoprolol can be increased when it is combined with Cobicistat.Approved
CocaineThe serum concentration of Metoprolol can be increased when it is combined with Cocaine.Approved, Illicit
CodeineThe serum concentration of Metoprolol can be increased when it is combined with Codeine.Approved, Illicit
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Metoprolol.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Conivaptan is combined with Metoprolol.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Metoprolol.Vet Approved
CrizotinibMetoprolol may increase the bradycardic activities of Crizotinib.Approved
CryptenamineMetoprolol may increase the hypotensive activities of Cryptenamine.Approved
CurcuminCurcumin may decrease the antihypertensive activities of Metoprolol.Investigational
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Metoprolol.Approved
CyclopenthiazideMetoprolol may increase the hypotensive activities of Cyclopenthiazide.Experimental
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Metoprolol.Approved, Investigational
CyclosporineThe serum concentration of Metoprolol can be increased when it is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyclothiazideMetoprolol may increase the hypotensive activities of Cyclothiazide.Approved
CymarinMetoprolol may increase the bradycardic activities of Cymarin.Experimental
Cyproterone acetateThe serum concentration of Metoprolol can be increased when it is combined with Cyproterone acetate.Approved, Investigational
D-LimoneneD-Limonene may decrease the antihypertensive activities of Metoprolol.Investigational
Dabigatran etexilateThe serum concentration of the active metabolites of Dabigatran etexilate can be increased when Dabigatran etexilate is used in combination with Metoprolol.Approved
DabrafenibThe serum concentration of Metoprolol can be decreased when it is combined with Dabrafenib.Approved
DapagliflozinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dapagliflozin.Approved
DapoxetineThe serum concentration of Metoprolol can be increased when it is combined with Dapoxetine.Investigational
DarifenacinThe serum concentration of Metoprolol can be increased when it is combined with Darifenacin.Approved, Investigational
DarunavirThe serum concentration of Metoprolol can be increased when it is combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Metoprolol.Approved
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Metoprolol.Approved, Investigational
DecamethoniumDecamethonium may increase the bradycardic activities of Metoprolol.Approved
DelaprilMetoprolol may increase the hypotensive activities of Delapril.Experimental
DelavirdineThe serum concentration of Metoprolol can be increased when it is combined with Delavirdine.Approved
DemecariumDemecarium may increase the bradycardic activities of Metoprolol.Approved
DeramciclaneThe serum concentration of Metoprolol can be increased when it is combined with Deramciclane.Investigational
DeserpidineMetoprolol may increase the hypotensive activities of Deserpidine.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Metoprolol.Approved
DesipramineThe serum concentration of Metoprolol can be increased when it is combined with Desipramine.Approved
DeslanosideMetoprolol may increase the bradycardic activities of Deslanoside.Approved
DesloratadineThe serum concentration of Metoprolol can be increased when it is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe serum concentration of Metoprolol can be increased when it is combined with Desvenlafaxine.Approved
DeutetrabenazineThe metabolism of Deutetrabenazine can be decreased when combined with Metoprolol.Approved, Investigational
Dexchlorpheniramine maleateThe metabolism of Dexchlorpheniramine maleate can be decreased when combined with Metoprolol.Approved
DexfenfluramineThe serum concentration of Metoprolol can be increased when it is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe serum concentration of Metoprolol can be increased when it is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe serum concentration of Metoprolol can be increased when it is combined with Dexmethylphenidate.Approved
DextroamphetamineThe serum concentration of Metoprolol can be increased when it is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe serum concentration of Metoprolol can be increased when it is combined with Dextromethorphan.Approved
DextropropoxypheneThe serum concentration of Metoprolol can be increased when it is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DiacereinThe serum concentration of Metoprolol can be increased when it is combined with Diacerein.Approved, Investigational
DiazoxideDiazoxide may increase the hypotensive activities of Metoprolol.Approved
DichlorvosDichlorvos may increase the bradycardic activities of Metoprolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Diclofenamide.Approved
diethylnorspermineMetoprolol may increase the hypotensive activities of diethylnorspermine.Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Metoprolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Metoprolol.Approved
DigitoxinMetoprolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinMetoprolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Metoprolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydralazineDihydralazine may increase the hypotensive activities of Metoprolol.Investigational
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Metoprolol.Approved, Illicit
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
DiltiazemThe serum concentration of Metoprolol can be increased when it is combined with Diltiazem.Approved
Dimethyl sulfoxideThe serum concentration of Metoprolol can be increased when it is combined with Dimethyl sulfoxide.Approved, Vet Approved
DinutuximabThe risk or severity of adverse effects can be increased when Metoprolol is combined with Dinutuximab.Approved
DiphenhydramineThe serum concentration of Metoprolol can be increased when it is combined with Diphenhydramine.Approved
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Metoprolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Metoprolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Metoprolol.Experimental
DisulfiramThe serum concentration of Metoprolol can be increased when it is combined with Disulfiram.Approved
DobutamineMetoprolol may decrease the bronchodilatory activities of Dobutamine.Approved
DolasetronThe serum concentration of Metoprolol can be increased when it is combined with Dolasetron.Approved
DomperidoneThe metabolism of Domperidone can be decreased when combined with Metoprolol.Approved, Investigational, Vet Approved
DonepezilDonepezil may increase the bradycardic activities of Metoprolol.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Metoprolol.Approved
DorzolamideMetoprolol may increase the hypotensive activities of Dorzolamide.Approved
DosulepinThe serum concentration of Metoprolol can be increased when it is combined with Dosulepin.Approved
DoxazosinMetoprolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinThe serum concentration of Metoprolol can be increased when it is combined with Doxepin.Approved
DoxorubicinThe serum concentration of Metoprolol can be increased when it is combined with Doxorubicin.Approved, Investigational
DronedaroneThe serum concentration of Metoprolol can be increased when it is combined with Dronedarone.Approved
DroxicamDroxicam may decrease the antihypertensive activities of Metoprolol.Approved
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
DuloxetineThe serum concentration of Metoprolol can be increased when it is combined with Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Metoprolol.Investigational
DyphyllineMetoprolol may decrease the bronchodilatory activities of Dyphylline.Approved
E-6201E-6201 may decrease the antihypertensive activities of Metoprolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Metoprolol.Approved
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Metoprolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Metoprolol.Approved
EfavirenzThe serum concentration of Metoprolol can be increased when it is combined with Efavirenz.Approved, Investigational
EfonidipineMetoprolol may increase the hypotensive activities of Efonidipine.Approved
EletriptanThe metabolism of Eletriptan can be decreased when combined with Metoprolol.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Metoprolol.Approved
EmpagliflozinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatMetoprolol may increase the hypotensive activities of Enalaprilat.Approved
EnasidenibThe serum concentration of Metoprolol can be increased when it is combined with Enasidenib.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Metoprolol.Approved, Investigational, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Metoprolol.Investigational
EndralazineEndralazine may increase the hypotensive activities of Metoprolol.Experimental
EntacaponeThe serum concentration of Metoprolol can be increased when it is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Metoprolol can be increased when it is combined with Enzalutamide.Approved
EpanololMetoprolol may increase the hypotensive activities of Epanolol.Experimental
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Epibatidine.Experimental
EpinastineThe serum concentration of Metoprolol can be increased when it is combined with Epinastine.Approved, Investigational
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Metoprolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eplerenone.Approved
EpoprostenolMetoprolol may increase the hypotensive activities of Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Eprosartan.Approved
Ergoloid mesylateMetoprolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineMetoprolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Metoprolol.Approved, Investigational
EscitalopramThe serum concentration of Metoprolol can be increased when it is combined with Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe metabolism of Metoprolol can be decreased when combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Metoprolol.Investigational
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Metoprolol.Approved
EsomeprazoleThe metabolism of Metoprolol can be decreased when combined with Esomeprazole.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when Metoprolol is combined with Etacrynic acid.Approved
EtanerceptEtanercept may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Metoprolol.Experimental
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Metoprolol.Approved, Illicit
EtodolacEtodolac may decrease the antihypertensive activities of Metoprolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
EtomidateEtomidate may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
EtoperidoneThe serum concentration of Metoprolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibThe serum concentration of Metoprolol can be increased when it is combined with Etoricoxib.Approved, Investigational
EtravirineThe metabolism of Metoprolol can be decreased when combined with Etravirine.Approved
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Metoprolol.Approved
exisulindexisulind may decrease the antihypertensive activities of Metoprolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Metoprolol.Experimental
FelodipineThe serum concentration of Metoprolol can be increased when it is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Metoprolol.Approved
FenfluramineThe serum concentration of Metoprolol can be increased when it is combined with Fenfluramine.Illicit, Investigational, Withdrawn
FenoldopamMetoprolol may increase the hypotensive activities of Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Metoprolol.Approved
FenoterolMetoprolol may decrease the bronchodilatory activities of Fenoterol.Approved, Investigational
FentanylFentanyl may increase the bradycardic activities of Metoprolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Metoprolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Metoprolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Metoprolol.Experimental
Ferulic acidMetoprolol may increase the hypotensive activities of Ferulic acid.Experimental
FesoterodineThe serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Metoprolol.Approved
FexofenadineThe serum concentration of Metoprolol can be increased when it is combined with Fexofenadine.Approved
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metoprolol.Approved, Investigational
FingolimodMetoprolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
FlecainideThe serum concentration of Metoprolol can be increased when it is combined with Flecainide.Approved, Withdrawn
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Metoprolol.Approved, Withdrawn
FluconazoleThe metabolism of Metoprolol can be decreased when combined with Fluconazole.Approved
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Metoprolol.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Metoprolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Metoprolol.Experimental
FluoxetineThe serum concentration of Metoprolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FluphenazineThe serum concentration of Metoprolol can be increased when it is combined with Fluphenazine.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
FluvastatinThe serum concentration of Metoprolol can be increased when it is combined with Fluvastatin.Approved
FluvoxamineThe serum concentration of Metoprolol can be increased when it is combined with Fluvoxamine.Approved, Investigational
FormoterolThe metabolism of Formoterol can be decreased when combined with Metoprolol.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Fosinopril.Approved
FosphenytoinThe metabolism of Metoprolol can be increased when combined with Fosphenytoin.Approved
FurazolidoneFurazolidone may increase the hypotensive activities of Metoprolol.Approved, Investigational, Vet Approved
FurosemideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Furosemide.Approved, Vet Approved
GalantamineGalantamine may increase the bradycardic activities of Metoprolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Metoprolol.Approved
GefitinibThe serum concentration of Metoprolol can be increased when it is combined with Gefitinib.Approved, Investigational
GemfibrozilThe metabolism of Metoprolol can be decreased when combined with Gemfibrozil.Approved
GitoformateMetoprolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideMetoprolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideMetoprolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideMetoprolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideMetoprolol may increase the hypoglycemic activities of Glipizide.Approved
GliquidoneMetoprolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideMetoprolol may increase the hypoglycemic activities of Glisoxepide.Approved, Investigational
GlyburideMetoprolol may increase the hypoglycemic activities of Glyburide.Approved
Glycerol PhenylbutyrateThe serum concentration of Metoprolol can be increased when it is combined with Glycerol Phenylbutyrate.Approved
GranisetronThe serum concentration of Metoprolol can be increased when it is combined with Granisetron.Approved, Investigational
GTS-21The risk or severity of adverse effects can be increased when Metoprolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Metoprolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
GuanadrelGuanadrel may increase the hypotensive activities of Metoprolol.Approved
GuanazodineMetoprolol may increase the hypotensive activities of Guanazodine.Experimental
GuanethidineMetoprolol may increase the hypotensive activities of Guanethidine.Approved
GuanfacineGuanfacine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
GuanoclorMetoprolol may increase the hypotensive activities of Guanoclor.Experimental
GuanoxabenzMetoprolol may increase the hypotensive activities of Guanoxabenz.Experimental
GuanoxanMetoprolol may increase the hypotensive activities of Guanoxan.Experimental
HalofantrineThe serum concentration of Metoprolol can be increased when it is combined with Halofantrine.Approved
HaloperidolThe serum concentration of Metoprolol can be increased when it is combined with Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Metoprolol.Approved, Vet Approved
HarmalineHarmaline may increase the hypotensive activities of Metoprolol.Experimental
HexamethoniumMetoprolol may increase the hypotensive activities of Hexamethonium.Experimental
HexobarbitalHexobarbital may increase the hypotensive activities of Metoprolol.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Metoprolol.Investigational
HistamineThe serum concentration of Metoprolol can be increased when it is combined with Histamine.Approved, Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Metoprolol.Investigational
HydracarbazineHydracarbazine may increase the hypotensive activities of Metoprolol.Experimental
HydralazineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydrocodoneThe metabolism of Hydrocodone can be decreased when combined with Metoprolol.Approved, Illicit
HydroflumethiazideMetoprolol may increase the hypotensive activities of Hydroflumethiazide.Approved, Investigational
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Metoprolol.Approved, Illicit
HydroxychloroquineThe serum concentration of Metoprolol can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyureaThe serum concentration of Metoprolol can be increased when it is combined with Hydroxyurea.Approved
HydroxyzineThe serum concentration of Metoprolol can be increased when it is combined with Hydroxyzine.Approved
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Metoprolol.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Metoprolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Metoprolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Metoprolol.Approved
IdarubicinThe serum concentration of Metoprolol can be increased when it is combined with Idarubicin.Approved
IloperidoneThe metabolism of Iloperidone can be decreased when combined with Metoprolol.Approved
IloprostIloprost may increase the hypotensive activities of Metoprolol.Approved, Investigational
ImatinibThe serum concentration of Metoprolol can be increased when it is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Imidapril is combined with Metoprolol.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Metoprolol.Experimental
ImipramineThe serum concentration of Metoprolol can be increased when it is combined with Imipramine.Approved
IndacaterolMetoprolol may decrease the bronchodilatory activities of Indacaterol.Approved
IndalpineThe serum concentration of Metoprolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Indapamide.Approved
IndenololMetoprolol may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe serum concentration of Metoprolol can be increased when it is combined with Indinavir.Approved
indisulamThe serum concentration of Metoprolol can be increased when it is combined with indisulam.Investigational
IndobufenIndobufen may decrease the antihypertensive activities of Metoprolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Metoprolol.Withdrawn
IndoraminMetoprolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanMetoprolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkMetoprolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Metoprolol.Experimental
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Metoprolol.Approved
IproclozideIproclozide may increase the hypotensive activities of Metoprolol.Withdrawn
IproniazidIproniazid may increase the hypotensive activities of Metoprolol.Withdrawn
IrbesartanThe serum concentration of Metoprolol can be increased when it is combined with Irbesartan.Approved, Investigational
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Metoprolol.Approved
IsoetarineMetoprolol may decrease the bronchodilatory activities of Isoetarine.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Metoprolol.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Metoprolol.Approved, Investigational, Withdrawn
IsoniazidThe serum concentration of Metoprolol can be increased when it is combined with Isoniazid.Approved
IsoprenalineMetoprolol may decrease the bronchodilatory activities of Isoprenaline.Approved
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Dinitrate.Approved
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Metoprolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Isradipine.Approved
ItraconazoleThe serum concentration of Metoprolol can be increased when it is combined with Itraconazole.Approved, Investigational
IvabradineMetoprolol may increase the bradycardic activities of Ivabradine.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Metoprolol.Approved
KebuzoneKebuzone may decrease the antihypertensive activities of Metoprolol.Experimental
KetanserinKetanserin may increase the hypotensive activities of Metoprolol.Investigational
KetoconazoleThe serum concentration of Metoprolol can be increased when it is combined with Ketoconazole.Approved, Investigational
KetoprofenKetoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Metoprolol.Approved
LabetalolThe serum concentration of Metoprolol can be increased when it is combined with Labetalol.Approved
LacidipineMetoprolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LacosamideMetoprolol may increase the atrioventricular blocking (AV block) activities of Lacosamide.Approved
Lanatoside CMetoprolol may increase the bradycardic activities of Lanatoside C.Experimental
LanreotideMetoprolol may increase the bradycardic activities of Lanreotide.Approved
LansoprazoleThe serum concentration of Metoprolol can be increased when it is combined with Lansoprazole.Approved, Investigational
LatanoprostMetoprolol may increase the hypotensive activities of Latanoprost.Approved, Investigational
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Metoprolol.Approved
LeflunomideLeflunomide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
LercanidipineLercanidipine may increase the hypotensive activities of Metoprolol.Approved, Investigational
LetermovirThe metabolism of Letermovir can be decreased when combined with Metoprolol.Approved
LevobunololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Metoprolol.Approved, Investigational
LevodopaMetoprolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Metoprolol.Approved
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
LevosalbutamolThe serum concentration of Metoprolol can be increased when it is combined with Levosalbutamol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Levosimendan is combined with Metoprolol.Approved, Investigational
LidocaineThe serum concentration of Metoprolol can be increased when it is combined with Lidocaine.Approved, Vet Approved
LinsidomineMetoprolol may increase the hypotensive activities of Linsidomine.Experimental
LisinoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Metoprolol.Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Metoprolol.Approved, Investigational
LobeglitazoneThe metabolism of Metoprolol can be decreased when combined with Lobeglitazone.Approved, Investigational
LobelineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
LomustineThe serum concentration of Metoprolol can be increased when it is combined with Lomustine.Approved
LonazolacLonazolac may decrease the antihypertensive activities of Metoprolol.Experimental
LoperamideThe metabolism of Loperamide can be decreased when combined with Metoprolol.Approved
LopinavirThe serum concentration of Metoprolol can be increased when it is combined with Lopinavir.Approved
LoratadineThe serum concentration of Metoprolol can be increased when it is combined with Loratadine.Approved
LorcaserinThe serum concentration of Metoprolol can be increased when it is combined with Lorcaserin.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Losartan.Approved
LovastatinThe serum concentration of Metoprolol can be increased when it is combined with Lovastatin.Approved, Investigational
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
LucinactantMetoprolol may increase the bradycardic activities of Lucinactant.Approved, Investigational
LuliconazoleThe serum concentration of Metoprolol can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Metoprolol can be decreased when it is combined with Lumacaftor.Approved
LumefantrineThe serum concentration of Metoprolol can be increased when it is combined with Lumefantrine.Approved
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MacitentanMetoprolol may increase the hypotensive activities of Macitentan.Approved
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Metoprolol.Approved
MalathionMalathion may increase the bradycardic activities of Metoprolol.Approved, Investigational
ManidipineThe serum concentration of Metoprolol can be increased when it is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mannitol.Approved, Investigational
MaprotilineThe metabolism of Maprotiline can be decreased when combined with Metoprolol.Approved
MasoprocolMasoprocol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MebanazineMebanazine may increase the hypotensive activities of Metoprolol.Withdrawn
MecamylamineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Mecamylamine.Approved
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Metoprolol.Approved
MefloquineThe serum concentration of Metoprolol can be increased when it is combined with Mefloquine.Approved
MeloxicamMeloxicam may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Metoprolol.Approved, Investigational
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Metoprolol.Investigational, Withdrawn
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Metoprolol.Approved, Vet Approved
MepyramineThe serum concentration of Metoprolol can be increased when it is combined with Mepyramine.Approved, Vet Approved
MequitazineThe metabolism of Mequitazine can be decreased when combined with Metoprolol.Approved
MesalazineMesalazine may decrease the antihypertensive activities of Metoprolol.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Metoprolol.Approved, Investigational
MetahexamideMetoprolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Metoprolol.Investigational, Withdrawn
MethacholineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Methacholine.Approved
MethadoneThe serum concentration of Metoprolol can be increased when it is combined with Methadone.Approved
MethamphetamineThe serum concentration of Metoprolol can be increased when it is combined with Methamphetamine.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Metoprolol.Investigational
MethazolamideThe serum concentration of Metoprolol can be increased when it is combined with Methazolamide.Approved
MethimazoleThe serum concentration of Metoprolol can be increased when it is combined with Methimazole.Approved
MethohexitalMethohexital may increase the hypotensive activities of Metoprolol.Approved
MethoserpidineMetoprolol may increase the hypotensive activities of Methoserpidine.Experimental
MethotrimeprazineThe serum concentration of Metoprolol can be increased when it is combined with Methotrimeprazine.Approved
MethoxsalenThe serum concentration of Metoprolol can be increased when it is combined with Methoxsalen.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Metoprolol.Approved, Investigational, Vet Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Metoprolol.Approved
MethyldopaThe risk or severity of adverse effects can be increased when Metoprolol is combined with Methyldopa.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Metoprolol.Approved, Investigational
MethylergometrineMetoprolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylnaltrexoneThe serum concentration of Metoprolol can be increased when it is combined with Methylnaltrexone.Approved
MethylphenidateThe serum concentration of Metoprolol can be increased when it is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Metoprolol.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Metoprolol.Approved, Illicit, Withdrawn
MetildigoxinMetoprolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metipranolol.Approved
MetoclopramideThe serum concentration of Metoprolol can be increased when it is combined with Metoclopramide.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Metolazone.Approved
MetyrosineMetoprolol may increase the hypotensive activities of Metyrosine.Approved
MexiletineThe metabolism of Mexiletine can be decreased when combined with Metoprolol.Approved
MianserinThe serum concentration of Metoprolol can be increased when it is combined with Mianserin.Approved, Investigational
MibefradilThe serum concentration of Metoprolol can be increased when it is combined with Mibefradil.Investigational, Withdrawn
MiconazoleThe serum concentration of Metoprolol can be increased when it is combined with Miconazole.Approved, Investigational, Vet Approved
MidodrineThe serum concentration of Metoprolol can be increased when it is combined with Midodrine.Approved
MidostaurinThe serum concentration of Metoprolol can be increased when it is combined with Midostaurin.Approved
MifepristoneThe serum concentration of Metoprolol can be increased when it is combined with Mifepristone.Approved, Investigational
MilnacipranThe serum concentration of Metoprolol can be increased when it is combined with Milnacipran.Approved
MinaprineMinaprine may increase the bradycardic activities of Metoprolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Minoxidil.Approved
MirabegronMirabegron may decrease the antihypertensive activities of Metoprolol.Approved
MirodenafilMirodenafil may increase the antihypertensive activities of Metoprolol.Investigational
MirtazapineThe serum concentration of Metoprolol can be increased when it is combined with Mirtazapine.Approved
MizoribineMizoribine may decrease the antihypertensive activities of Metoprolol.Investigational
MoclobemideThe serum concentration of Metoprolol can be increased when it is combined with Moclobemide.Approved
ModafinilThe metabolism of Metoprolol can be decreased when combined with Modafinil.Approved, Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Metoprolol.Experimental
MolsidomineMolsidomine may increase the hypotensive activities of Metoprolol.Approved, Investigational
MoricizineMoricizine may increase the hypotensive activities of Metoprolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Metoprolol.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved, Investigational
MuzolimineMetoprolol may increase the hypotensive activities of Muzolimine.Experimental
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Metoprolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Nabilone is combined with Metoprolol.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Metoprolol.Approved
NadololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Metoprolol.Approved
NaftopidilMetoprolol may increase the hypotensive activities of Naftopidil.Investigational
NaloxegolThe serum concentration of Metoprolol can be increased when it is combined with Naloxegol.Approved
NaphazolineNaphazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
NateglinideThe metabolism of Nateglinide can be decreased when combined with Metoprolol.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Metoprolol.Approved, Investigational
NefazodoneThe serum concentration of Metoprolol can be increased when it is combined with Nefazodone.Approved, Withdrawn
NelfinavirThe serum concentration of Metoprolol can be increased when it is combined with Nelfinavir.Approved
NeostigmineNeostigmine may increase the bradycardic activities of Metoprolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Metoprolol.Approved
NesiritideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nesiritide.Approved, Investigational
NetupitantThe metabolism of Netupitant can be decreased when combined with Metoprolol.Approved
NevirapineThe serum concentration of Metoprolol can be increased when it is combined with Nevirapine.Approved
NiacinThe serum concentration of Metoprolol can be increased when it is combined with Niacin.Approved, Investigational, Nutraceutical
NialamideNialamide may increase the hypotensive activities of Metoprolol.Withdrawn
NicardipineThe serum concentration of Metoprolol can be increased when it is combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Metoprolol.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Metoprolol.Approved, Investigational
NicotinamideThe serum concentration of Metoprolol can be increased when it is combined with Nicotinamide.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Metoprolol.Approved
NifedipineThe serum concentration of Metoprolol can be increased when it is combined with Nifedipine.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Metoprolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Metoprolol.Approved
NiguldipineMetoprolol may increase the hypotensive activities of Niguldipine.Experimental
NilotinibThe serum concentration of Metoprolol can be increased when it is combined with Nilotinib.Approved, Investigational
NilvadipineMetoprolol may increase the hypotensive activities of Nilvadipine.Approved, Investigational
NimesulideNimesulide may decrease the antihypertensive activities of Metoprolol.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nimodipine.Approved
NisoldipineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of adverse effects can be increased when Nitrendipine is combined with Metoprolol.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Nitric Oxide is combined with Metoprolol.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Metoprolol.Investigational
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Metoprolol.Approved, Investigational, Vet Approved
NitroglycerinThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Metoprolol is combined with Nitroprusside.Approved
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
NortriptylineThe serum concentration of Metoprolol can be increased when it is combined with Nortriptyline.Approved
ObinutuzumabMetoprolol may increase the hypotensive activities of Obinutuzumab.Approved
OctamoxinOctamoxin may increase the hypotensive activities of Metoprolol.Withdrawn
OctreotideOctreotide may increase the bradycardic activities of Metoprolol.Approved, Investigational
OlanzapineThe serum concentration of Metoprolol can be increased when it is combined with Olanzapine.Approved, Investigational
OleandrinMetoprolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Olmesartan.Approved, Investigational
OlodaterolMetoprolol may decrease the bronchodilatory activities of Olodaterol.Approved
OlopatadineOlopatadine may decrease the antihypertensive activities of Metoprolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Metoprolol.Approved
OmapatrilatMetoprolol may increase the hypotensive activities of Omapatrilat.Investigational
OmeprazoleThe serum concentration of Metoprolol can be increased when it is combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronThe serum concentration of Metoprolol can be increased when it is combined with Ondansetron.Approved
OrciprenalineMetoprolol may decrease the bronchodilatory activities of Orciprenaline.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Metoprolol.Vet Approved
OspemifeneThe serum concentration of Metoprolol can be increased when it is combined with Ospemifene.Approved
OuabainMetoprolol may increase the bradycardic activities of Ouabain.Approved
OxamniquineThe serum concentration of Metoprolol can be increased when it is combined with Oxamniquine.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Metoprolol.Approved
OxprenololThe serum concentration of Metoprolol can be increased when it is combined with Oxprenolol.Approved
OxybutyninThe serum concentration of Metoprolol can be increased when it is combined with Oxybutynin.Approved, Investigational
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Metoprolol.Approved, Illicit, Investigational
OxymetazolineOxymetazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
OxymetholoneThe serum concentration of Metoprolol can be increased when it is combined with Oxymetholone.Approved, Illicit
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Metoprolol.Approved, Investigational, Vet Approved
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Metoprolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Metoprolol.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Metoprolol.Approved, Investigational
PanobinostatThe serum concentration of Metoprolol can be increased when it is combined with Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Metoprolol can be decreased when combined with Pantoprazole.Approved
PapaverineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Papaverine.Approved
ParaoxonParaoxon may increase the bradycardic activities of Metoprolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Metoprolol.Approved
PargylinePargyline may increase the hypotensive activities of Metoprolol.Approved
ParoxetineThe serum concentration of Metoprolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Metoprolol.Investigational
PasireotideMetoprolol may increase the bradycardic activities of Pasireotide.Approved
PazopanibThe serum concentration of Metoprolol can be increased when it is combined with Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Metoprolol can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololThe risk or severity of adverse effects can be increased when Metoprolol is combined with Penbutolol.Approved, Investigational
PentamidineThe serum concentration of Metoprolol can be increased when it is combined with Pentamidine.Approved
PentobarbitalPentobarbital may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
PentoliniumMetoprolol may increase the hypotensive activities of Pentolinium.Approved
PentoxifyllinePentoxifylline may increase the hypotensive activities of Metoprolol.Approved, Investigational
PerazinePerazine may increase the hypotensive activities of Metoprolol.Investigational
PergolideThe serum concentration of Metoprolol can be increased when it is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerhexilineThe serum concentration of Metoprolol can be increased when it is combined with Perhexiline.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Perindopril.Approved
PerospironeThe metabolism of Perospirone can be decreased when combined with Metoprolol.Approved
PerphenazineThe serum concentration of Metoprolol can be increased when it is combined with Perphenazine.Approved
PeruvosideMetoprolol may increase the bradycardic activities of Peruvoside.Experimental
PethidineThe metabolism of Pethidine can be decreased when combined with Metoprolol.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Metoprolol.Withdrawn
PhenelzinePhenelzine may increase the hypotensive activities of Metoprolol.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Metoprolol.Approved, Investigational, Withdrawn
PheniprazinePheniprazine may increase the hypotensive activities of Metoprolol.Withdrawn
PhenobarbitalPhenobarbital may increase the hypotensive activities of Metoprolol.Approved
PhenoxybenzamineMetoprolol may increase the hypotensive activities of Phenoxybenzamine.Approved
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Metoprolol.Withdrawn
PhentermineThe serum concentration of Metoprolol can be increased when it is combined with Phentermine.Approved, Illicit
PhentolamineMetoprolol may increase the hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
Phenylbutyric acidThe serum concentration of Metoprolol can be increased when it is combined with Phenylbutyric acid.Approved, Investigational
PhenylpropanolamineMetoprolol may decrease the bronchodilatory activities of Phenylpropanolamine.Approved, Vet Approved, Withdrawn
PhenytoinThe metabolism of Metoprolol can be increased when combined with Phenytoin.Approved, Vet Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Metoprolol.Approved
PilocarpineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Pilocarpine.Approved
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
PimozideThe serum concentration of Metoprolol can be increased when it is combined with Pimozide.Approved
PinacidilPinacidil may increase the hypotensive activities of Metoprolol.Withdrawn
PindololThe serum concentration of Metoprolol can be increased when it is combined with Pindolol.Approved
PioglitazoneThe serum concentration of Metoprolol can be increased when it is combined with Pioglitazone.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Metoprolol.Approved, Investigational
PiperazineThe metabolism of Piperazine can be decreased when combined with Metoprolol.Approved, Vet Approved
PipotiazineThe serum concentration of Metoprolol can be increased when it is combined with Pipotiazine.Approved, Investigational
PirbuterolMetoprolol may decrease the bronchodilatory activities of Pirbuterol.Approved
PirfenidonePirfenidone may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
PirlindolePirlindole may increase the hypotensive activities of Metoprolol.Approved
PiroxicamPiroxicam may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Metoprolol.Experimental
PivhydrazinePivhydrazine may increase the hypotensive activities of Metoprolol.Withdrawn
Platelet Activating FactorMetoprolol may increase the hypotensive activities of Platelet Activating Factor.Experimental
PolythiazideMetoprolol may increase the hypotensive activities of Polythiazide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Metoprolol.Approved
Poractant alfaMetoprolol may increase the bradycardic activities of Poractant alfa.Approved
PramipexoleThe risk or severity of adverse effects can be increased when Pramipexole is combined with Metoprolol.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Metoprolol.Experimental, Investigational
PravastatinThe serum concentration of Metoprolol can be increased when it is combined with Pravastatin.Approved
PraziquantelThe serum concentration of Metoprolol can be increased when it is combined with Praziquantel.Approved, Vet Approved
PrazosinMetoprolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrimaquineThe serum concentration of Metoprolol can be increased when it is combined with Primaquine.Approved
PrimidonePrimidone may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
ProcainamideThe metabolism of Procainamide can be decreased when combined with Metoprolol.Approved
ProcarbazineProcarbazine may increase the hypotensive activities of Metoprolol.Approved
ProcaterolMetoprolol may decrease the bronchodilatory activities of Procaterol.Approved, Investigational
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Metoprolol.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Metoprolol.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Metoprolol.Experimental
ProguanilThe serum concentration of Metoprolol can be increased when it is combined with Proguanil.Approved
PromazineThe serum concentration of Metoprolol can be increased when it is combined with Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Metoprolol can be increased when it is combined with Promethazine.Approved
PropacetamolPropacetamol may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
PropafenoneThe serum concentration of Metoprolol can be increased when it is combined with Propafenone.Approved
PropericiazinePropericiazine may increase the hypotensive activities of Metoprolol.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Metoprolol.Vet Approved
PropofolThe serum concentration of Metoprolol can be increased when it is combined with Propofol.Approved, Investigational, Vet Approved
Propoxyphene napsylateThe serum concentration of Metoprolol can be increased when it is combined with Propoxyphene napsylate.Approved
PropranololThe serum concentration of Metoprolol can be increased when it is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Metoprolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Metoprolol.Experimental
ProscillaridinMetoprolol may increase the bradycardic activities of Proscillaridin.Experimental
ProtriptylineThe metabolism of Protriptyline can be decreased when combined with Metoprolol.Approved
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Metoprolol.Approved
PseudoephedrinePseudoephedrine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Metoprolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Metoprolol.Approved
PyrimethamineThe serum concentration of Metoprolol can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
QuetiapineThe serum concentration of Metoprolol can be increased when it is combined with Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Quinapril.Approved, Investigational
QuinidineThe serum concentration of Metoprolol can be increased when it is combined with Quinidine.Approved
QuinineThe serum concentration of Metoprolol can be increased when it is combined with Quinine.Approved
RabeprazoleThe serum concentration of Metoprolol can be increased when it is combined with Rabeprazole.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Ramipril is combined with Metoprolol.Approved
RanitidineThe serum concentration of Metoprolol can be increased when it is combined with Ranitidine.Approved
RanolazineThe serum concentration of Metoprolol can be increased when it is combined with Ranolazine.Approved, Investigational
RasagilineRasagiline may increase the hypotensive activities of Metoprolol.Approved
ReboxetineThe serum concentration of Metoprolol can be increased when it is combined with Reboxetine.Approved, Investigational
RegorafenibRegorafenib may increase the bradycardic activities of Metoprolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Metoprolol.Approved
RemikirenRemikiren may increase the hypotensive activities of Metoprolol.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Metoprolol.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Metoprolol.Investigational
RescinnamineMetoprolol may increase the hypotensive activities of Rescinnamine.Approved
ReserpineReserpine may increase the hypotensive activities of Metoprolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Metoprolol.Approved, Experimental, Investigational
RheinThe serum concentration of Metoprolol can be increased when it is combined with Rhein.Experimental
RifampicinThe metabolism of Metoprolol can be increased when combined with Rifampicin.Approved
RifapentineThe serum concentration of Metoprolol can be decreased when it is combined with Rifapentine.Approved
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Metoprolol.Approved, Investigational
RilmenidineRilmenidine may increase the hypotensive activities of Metoprolol.Investigational
RiociguatThe risk or severity of adverse effects can be increased when Metoprolol is combined with Riociguat.Approved
RisperidoneThe serum concentration of Metoprolol can be increased when it is combined with Risperidone.Approved, Investigational
RitodrineMetoprolol may decrease the bronchodilatory activities of Ritodrine.Approved, Investigational
RitonavirThe serum concentration of Metoprolol can be increased when it is combined with Ritonavir.Approved, Investigational
RituximabMetoprolol may increase the hypotensive activities of Rituximab.Approved
RivastigmineThe serum concentration of Metoprolol can be increased when it is combined with Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Metoprolol.Investigational, Withdrawn
RolapitantThe serum concentration of Metoprolol can be increased when it is combined with Rolapitant.Approved
RopiniroleThe serum concentration of Metoprolol can be increased when it is combined with Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Metoprolol.Approved
RosiglitazoneThe serum concentration of Metoprolol can be increased when it is combined with Rosiglitazone.Approved, Investigational
RotigotineThe serum concentration of Metoprolol can be increased when it is combined with Rotigotine.Approved
RucaparibThe metabolism of Rucaparib can be decreased when combined with Metoprolol.Approved, Investigational
RupatadineThe metabolism of Rupatadine can be decreased when combined with Metoprolol.Approved
RutinThe serum concentration of Metoprolol can be increased when it is combined with Rutin.Experimental, Investigational
RuxolitinibRuxolitinib may increase the bradycardic activities of Metoprolol.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Metoprolol.Approved
SafrazineSafrazine may increase the hypotensive activities of Metoprolol.Withdrawn
SalbutamolMetoprolol may decrease the bronchodilatory activities of Salbutamol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Metoprolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Metoprolol.Approved, Vet Approved
SalmeterolMetoprolol may decrease the bronchodilatory activities of Salmeterol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Metoprolol.Approved
SaprisartanMetoprolol may increase the hypotensive activities of Saprisartan.Experimental
SaquinavirThe serum concentration of Metoprolol can be increased when it is combined with Saquinavir.Approved, Investigational
SecobarbitalSecobarbital may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
SelegilineThe serum concentration of Metoprolol can be increased when it is combined with Selegiline.Approved, Investigational, Vet Approved
SelexipagMetoprolol may increase the hypotensive activities of Selexipag.Approved
SemapimodSemapimod may decrease the antihypertensive activities of Metoprolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Metoprolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Metoprolol.Investigational
SertindoleThe metabolism of Sertindole can be decreased when combined with Metoprolol.Approved, Investigational, Withdrawn
SertralineThe serum concentration of Metoprolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Metoprolol.Approved, Vet Approved
SildenafilThe serum concentration of Metoprolol can be increased when it is combined with Sildenafil.Approved, Investigational
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Metoprolol.Approved
SimvastatinThe serum concentration of Metoprolol can be increased when it is combined with Simvastatin.Approved
SitaxentanMetoprolol may increase the hypotensive activities of Sitaxentan.Approved, Investigational, Withdrawn
Sodium NitriteThe risk or severity of adverse effects can be increased when Sodium Nitrite is combined with Metoprolol.Approved
SorafenibThe serum concentration of Metoprolol can be increased when it is combined with Sorafenib.Approved, Investigational
SotalolThe risk or severity of adverse effects can be increased when Metoprolol is combined with Sotalol.Approved
SparteineThe serum concentration of Metoprolol can be increased when it is combined with Sparteine.Experimental
SpiraprilMetoprolol may increase the hypotensive activities of Spirapril.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Metoprolol.Investigational
StiripentolThe serum concentration of Metoprolol can be increased when it is combined with Stiripentol.Approved
StreptokinaseThe risk or severity of adverse effects can be increased when Streptokinase is combined with Metoprolol.Approved, Investigational
SufentanilMetoprolol may increase the bradycardic activities of Sufentanil.Approved, Investigational
SulconazoleThe serum concentration of Metoprolol can be increased when it is combined with Sulconazole.Approved
SulfanilamideThe serum concentration of Metoprolol can be increased when it is combined with Sulfanilamide.Approved
SulfaphenazoleThe serum concentration of Metoprolol can be increased when it is combined with Sulfaphenazole.Approved
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Metoprolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Metoprolol.Approved
SuprofenSuprofen may decrease the antihypertensive activities of Metoprolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Metoprolol.Experimental
TacrineTacrine may increase the bradycardic activities of Metoprolol.Investigational, Withdrawn
TadalafilTadalafil may increase the antihypertensive activities of Metoprolol.Approved, Investigational
TalinololMetoprolol may increase the hypotensive activities of Talinolol.Investigational
TamoxifenThe serum concentration of Metoprolol can be increased when it is combined with Tamoxifen.Approved
TamsulosinMetoprolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TapentadolThe serum concentration of Metoprolol can be increased when it is combined with Tapentadol.Approved
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Metoprolol.Investigational
TegaserodThe serum concentration of Metoprolol can be increased when it is combined with Tegaserod.Investigational, Withdrawn
TelithromycinThe serum concentration of Metoprolol can be increased when it is combined with Telithromycin.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Metoprolol is combined with Telmisartan.Approved, Investigational
TemocaprilMetoprolol may increase the hypotensive activities of Temocapril.Experimental, Investigational
TemsirolimusThe serum concentration of Metoprolol can be increased when it is combined with Temsirolimus.Approved
TenidapTenidap may decrease the antihypertensive activities of Metoprolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Metoprolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Metoprolol.Vet Approved
TerazosinMetoprolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe serum concentration of Metoprolol can be increased when it is combined with Terbinafine.Approved, Investigational, Vet Approved
TerbutalineMetoprolol may decrease the bronchodilatory activities of Terbutaline.Approved
TerfenadineThe serum concentration of Metoprolol can be increased when it is combined with Terfenadine.Withdrawn
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Metoprolol.Approved
TerlipressinMetoprolol may increase the hypotensive activities of Terlipressin.Approved, Investigational
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Metoprolol.Investigational
TetrabenazineThe metabolism of Tetrabenazine can be decreased when combined with Metoprolol.Approved
TetrahydropalmatineMetoprolol may increase the hypotensive activities of Tetrahydropalmatine.Investigational
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Metoprolol.Approved, Investigational, Withdrawn
TheodrenalineMetoprolol may increase the hypotensive activities of Theodrenaline.Investigational
TheophyllineThe metabolism of Theophylline can be decreased when combined with Metoprolol.Approved
ThiamylalThiamylal may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Metoprolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Metoprolol.Withdrawn
ThiopentalThiopental may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
ThioproperazineThioproperazine may increase the hypotensive activities of Metoprolol.Approved
ThioridazineThe serum concentration of Metoprolol can be increased when it is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe serum concentration of Metoprolol can be increased when it is combined with Thiothixene.Approved
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Metoprolol.Approved
TiboloneMetoprolol may increase the hypotensive activities of Tibolone.Approved, Investigational
TicagrelorThe serum concentration of Metoprolol can be increased when it is combined with Ticagrelor.Approved
TiclopidineThe serum concentration of Metoprolol can be increased when it is combined with Ticlopidine.Approved
TicrynafenMetoprolol may increase the hypotensive activities of Ticrynafen.Withdrawn
TimololThe serum concentration of Metoprolol can be increased when it is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Metoprolol.Investigational
TioconazoleThe serum concentration of Metoprolol can be increased when it is combined with Tioconazole.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Metoprolol.Approved
TipranavirThe serum concentration of Metoprolol can be increased when it is combined with Tipranavir.Approved, Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
TofacitinibTofacitinib may increase the bradycardic activities of Metoprolol.Approved, Investigational
TolazamideMetoprolol may increase the hypoglycemic activities of Tolazamide.Approved
TolazolineMetoprolol may increase the hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideMetoprolol may increase the hypoglycemic activities of Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Metoprolol.Approved, Withdrawn
Tolfenamic AcidTolfenamic Acid may decrease the antihypertensive activities of Metoprolol.Approved
TolmetinTolmetin may decrease the antihypertensive activities of Metoprolol.Approved
TolonidineMetoprolol may increase the hypotensive activities of Tolonidine.Experimental
ToloxatoneToloxatone may increase the hypotensive activities of Metoprolol.Approved
TolterodineThe metabolism of Tolterodine can be decreased when combined with Metoprolol.Approved, Investigational
TopiramateThe metabolism of Metoprolol can be decreased when combined with Topiramate.Approved
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Metoprolol.Approved, Investigational
TorasemideThe risk or severity of adverse effects can be increased when Torasemide is combined with Metoprolol.Approved
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Metoprolol.Approved, Investigational
TramadolThe serum concentration of Metoprolol can be increased when it is combined with Tramadol.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Metoprolol is combined with Trandolapril.Approved
TranilastTranilast may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Metoprolol.Experimental
TranylcypromineThe serum concentration of Metoprolol can be increased when it is combined with Tranylcypromine.Approved
TravoprostMetoprolol may increase the hypotensive activities of Travoprost.Approved
TrazodoneThe metabolism of Trazodone can be decreased when combined with Metoprolol.Approved, Investigational
TreprostinilMetoprolol may increase the hypotensive activities of Treprostinil.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Tretinoin is combined with Metoprolol.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Metoprolol is combined with Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Metoprolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Metoprolol.Vet Approved
TrichlormethiazideMetoprolol may increase the hypotensive activities of Trichlormethiazide.Approved, Vet Approved
TrifluoperazineTrifluoperazine may increase the hypotensive activities of Metoprolol.Approved
TriflupromazineTriflupromazine may increase the hypotensive activities of Metoprolol.Approved, Vet Approved
TrimazosinMetoprolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimethaphanTrimethaphan may increase the hypotensive activities of Metoprolol.Approved, Investigational
TrimipramineThe metabolism of Trimipramine can be decreased when combined with Metoprolol.Approved
TripelennamineThe serum concentration of Metoprolol can be increased when it is combined with Tripelennamine.Approved, Vet Approved
TriprolidineThe serum concentration of Metoprolol can be increased when it is combined with Triprolidine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Metoprolol.Investigational
TrospiumThe serum concentration of Metoprolol can be increased when it is combined with Trospium.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Metoprolol.Approved
UdenafilUdenafil may increase the antihypertensive activities of Metoprolol.Approved, Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Metoprolol.Approved
UnoprostoneMetoprolol may increase the hypotensive activities of Unoprostone.Approved
UrapidilMetoprolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValbenazineThe metabolism of Valbenazine can be decreased when combined with Metoprolol.Approved, Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Metoprolol.Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metoprolol.Approved, Investigational
VardenafilVardenafil may increase the antihypertensive activities of Metoprolol.Approved
VareniclineThe risk or severity of adverse effects can be increased when Metoprolol is combined with Varenicline.Approved, Investigational
VemurafenibThe serum concentration of Metoprolol can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe serum concentration of Metoprolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe serum concentration of Metoprolol can be increased when it is combined with Verapamil.Approved
VernakalantThe serum concentration of Metoprolol can be increased when it is combined with Vernakalant.Approved, Investigational
VilanterolMetoprolol may decrease the bronchodilatory activities of Vilanterol.Approved
VilazodoneThe serum concentration of Metoprolol can be increased when it is combined with Vilazodone.Approved
VinblastineThe serum concentration of Metoprolol can be increased when it is combined with Vinblastine.Approved
VincamineMetoprolol may increase the hypotensive activities of Vincamine.Experimental
VincristineThe serum concentration of Vincristine can be increased when it is combined with Metoprolol.Approved, Investigational
VinorelbineThe serum concentration of Metoprolol can be increased when it is combined with Vinorelbine.Approved, Investigational
VinpocetineMetoprolol may increase the hypotensive activities of Vinpocetine.Investigational
VoriconazoleThe metabolism of Metoprolol can be decreased when combined with Voriconazole.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Metoprolol.Approved
XipamideMetoprolol may increase the hypotensive activities of Xipamide.Experimental
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Metoprolol.Approved
YohimbineThe serum concentration of Metoprolol can be increased when it is combined with Yohimbine.Approved, Vet Approved
ZafirlukastThe serum concentration of Metoprolol can be increased when it is combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Metoprolol.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
ZileutonZileuton may decrease the antihypertensive activities of Metoprolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Metoprolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneThe serum concentration of Metoprolol can be increased when it is combined with Ziprasidone.Approved
ZofenoprilMetoprolol may increase the hypotensive activities of Zofenopril.Experimental
ZolpidemThe metabolism of Zolpidem can be decreased when combined with Metoprolol.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Metoprolol.Withdrawn
ZucapsaicinThe serum concentration of Metoprolol can be increased when it is combined with Zucapsaicin.Approved
ZuclopenthixolThe metabolism of Zuclopenthixol can be decreased when combined with Metoprolol.Approved, Investigational
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take with food.

References

Synthesis Reference
US3998790
General References
  1. Authors unspecified: Effect of metoprolol CR/XL in chronic heart failure: Metoprolol CR/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF) Lancet. 1999 Jun 12;353(9169):2001-7. [PubMed:10376614]
External Links
Human Metabolome Database
HMDB01932
KEGG Drug
D02358
KEGG Compound
C07202
PubChem Compound
4171
PubChem Substance
46506211
ChemSpider
4027
BindingDB
25756
ChEBI
6904
ChEMBL
CHEMBL13
Therapeutic Targets Database
DAP000481
PharmGKB
PA450480
IUPHAR
553
Guide to Pharmacology
GtP Drug Page
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Metoprolol
ATC Codes
C07BB02 — Metoprolol and thiazidesC07AB02 — MetoprololC07BB52 — Metoprolol and thiazides, combinationsC07AB52 — Metoprolol, combinationsC07CB02 — Metoprolol and other diureticsC07FB02 — Metoprolol and other antihypertensives
AHFS Codes
  • 24:24.00 — Beta-adrenergic Blocking Agents
FDA label
Download (439 KB)
MSDS
Download (73.9 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedBasic SciencePharmacokinetic Profile / Plasma Concentrations1
1CompletedNot AvailableHealthy Volunteers4
1CompletedNot AvailableHealthy Volunteers / Pharmacokinetics of Mirabegron1
1CompletedNot AvailableNonvalvular Atrial Fibrillation1
1CompletedBasic ScienceAtopic Dermatitis (AD)1
1CompletedBasic ScienceDrug Biotransformation / Membrane Transport1
1CompletedBasic ScienceDrug Drug Interactions1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedDiagnosticCytochrome / Pharmacokinetics1
1CompletedTreatmentFasting2
1CompletedTreatmentFed1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHypertensive2
1CompletedTreatmentHypertensive / Peripheral Artery Disease (PAD)1
1CompletedTreatmentPlasmodium Infections1
1CompletedTreatmentPsoriasis1
1CompletedTreatmentTumors, Solid1
1CompletedTreatmentType 2 Diabetes Mellitus2
1Not Yet RecruitingBasic ScienceHealthy Volunteers / Pre Hypertension1
1Not Yet RecruitingOtherHealthy Volunteers1
1Unknown StatusBasic ScienceHealthy Volunteers1
1WithdrawnTreatmentHealthy Volunteers1
2Active Not RecruitingTreatmentCurrent or Recent History of Atrial Fibrillation1
2Active Not RecruitingTreatmentType 2 Diabetes Mellitus1
2CompletedPreventionCancer, Breast / Heart Failure, Unspecified1
2CompletedTreatmentAging / Cognitive Impairments / Hypertensive1
2CompletedTreatmentCardiovascular Disease (CVD) / Heart Diseases / Hypertensive / Vascular Diseases1
2RecruitingTreatmentAcute Coronary Syndromes (ACS) / Arterial Hypertension1
2RecruitingTreatmentConfirmed Genetic Diagnosis of Prader-Willi Syndrome1
2TerminatedTreatmentBMI >30 kg/m21
2TerminatedTreatmentCardiac Arrest / Severe ventricular arrhythmias / Sudden Cardiac Death / Ventricular Tachycardia (VT)1
2Unknown StatusBasic SciencePostural Orthostatic Tachycardia Syndrome (POTS)1
2Unknown StatusTreatmentAgeing / Cardiovascular Disease (CVD) / Trauma, Multiple1
2, 3CompletedPreventionDiabetes / Hypertensive1
2, 3CompletedTreatmentB Thalassemia1
2, 3CompletedTreatmentMitral Valve Insufficiency1
2, 3RecruitingTreatmentHypertensive1
2, 3RecruitingTreatmentHypertensive / Sleep Apnea Syndrome1
2, 3RecruitingTreatmentVentricular Arrythmias1
2, 3RecruitingTreatmentMinor burns1
2, 3WithdrawnTreatmentHypertensive1
3CompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Hypercholesterolaemia / Hypertensive / Type 2 Diabetes Mellitus1
3CompletedPreventionAtrial Flutter / Nonvalvular Atrial Fibrillation1
3CompletedPreventionLung Cancers / Nonvalvular Atrial Fibrillation1
3CompletedTreatmentBMI >30 kg/m2 / Hypertensive1
3CompletedTreatmentCardiac Remodeling / Cirrhotic Cardiomyopathy / Liver Cirrhosis1
3CompletedTreatmentCongestive Heart Failure (CHF)1
3CompletedTreatmentHigh Blood Pressure (Hypertension)1
3CompletedTreatmentHypertensive5
3CompletedTreatmentHypertensive / Peripheral Artery Disease (PAD)1
3CompletedTreatmentNonvalvular Atrial Fibrillation1
3CompletedTreatmentPrimary Arterial Hypertension1
3Not Yet RecruitingTreatmentCancer, Breast1
3RecruitingTreatmentHeart Diseases1
3RecruitingTreatmentPulmonary Disease, Chronic Obstructive1
3TerminatedTreatmentCongestive Heart Failure (CHF)1
3TerminatedTreatmentHeart Failure, Unspecified / Nonvalvular Atrial Fibrillation1
4Active Not RecruitingPreventionAdrenergic Beta-Receptor Blockader / Cardiomyopathy, Post-surgical / Troponin Levels1
4CompletedNot AvailableAcute Coronary Syndromes (ACS)1
4CompletedBasic ScienceBlood Pressures / Drug Overdose / Overdose of Beta-adrenergic Blocking Drug1
4CompletedBasic ScienceIdiopathic Dilated Cardiomyopathy1
4CompletedBasic ScienceMetabolic Syndromes1
4CompletedDiagnosticDiabetes1
4CompletedDiagnosticHypertensive2
4CompletedOtherHypertensive / Prehypertension2
4CompletedPreventionGraves´ Disease1
4CompletedPreventionHypertensive / Type 2 Diabetes Mellitus1
4CompletedPreventionNonvalvular Atrial Fibrillation / Surgery, Cardiac1
4CompletedSupportive CareHypertensive2
4CompletedTreatmentAcute Myocardial Infarction (AMI)1
4CompletedTreatmentAortic Valve Insufficiency1
4CompletedTreatmentCongestive Cardiomyopathy1
4CompletedTreatmentHeart Failure, Unspecified / Ventricular Dysfunction, Left1
4CompletedTreatmentHeart Rate and Rhythm Disorders1
4CompletedTreatmentHeart Valve Diseases1
4CompletedTreatmentHypertensive9
4CompletedTreatmentHypertensive / Type 2 Diabetes Mellitus1
4CompletedTreatmentRapid Ventricular Response Atrial Fibrillation1
4Not Yet RecruitingTreatmentCoronary Artery Disease2
4Not Yet RecruitingTreatmentNonvalvular Atrial Fibrillation1
4RecruitingBasic ScienceAcute Coronary Syndromes (ACS)1
4RecruitingBasic ScienceBlood Pressures1
4RecruitingOtherInterstitial Cystitis/Painful Bladder Syndrome / Myofascial Pelvic Pain1
4RecruitingTreatmentAcute Myocardial Infarction (AMI) / Non-ST Elevation Myocardial Infarction / ST Elevation Myocardial Infarction1
4RecruitingTreatmentAtrial Flutter / Nonvalvular Atrial Fibrillation1
4RecruitingTreatmentHypertension,Essential1
4RecruitingTreatmentNonvalvular Atrial Fibrillation / Permanent Atrial Fibrillation1
4RecruitingTreatmentSyncope, Vasovagal1
4TerminatedPreventionCardiovascular Disease (CVD) / Osteoarthritis (OA)1
4TerminatedPreventionProphylaxis of cardiomyopathy1
4TerminatedTreatmentAnginal Pain / Cardiac Diseases / Hypertensive / Vascular Diseases1
4TerminatedTreatmentHypertensive3
4Unknown StatusNot AvailableDiabetes Mellitus (DM) / Endothelial Function / Hypertensive1
4Unknown StatusNot AvailablePolyps, Nasal1
4Unknown StatusDiagnosticCoronary Artery Disease1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
4WithdrawnBasic ScienceBlood Pressures1
4WithdrawnBasic ScienceCentral Arterial Pressure1
4WithdrawnTreatmentChronic Obstructive Pulmonary Disease (COPD) / Heart Failure, Unspecified1
Not AvailableCompletedNot AvailableHeart Rate Variability / Hypertensive / Tachycardia1
Not AvailableCompletedNot AvailableHypertensive1
Not AvailableCompletedNot AvailableHypertensive / Multiple System Atrophy (MSA) / Progressive autonomic failure1
Not AvailableCompletedPreventionAtherosclerosis / Cardiovascular Disease (CVD) / Cerebral Arteriosclerosis / Coronary Heart Disease (CHD) / Diabetes Mellitus (DM) / Heart Diseases / Hypertensive1
Not AvailableCompletedTreatmentArrythmias / Nonvalvular Atrial Fibrillation1
Not AvailableCompletedTreatmentCVA (Cerebrovascular Accident) / Intracerebral Hemorrhage / Intracranial Hemorrhages1
Not AvailableCompletedTreatmentHypertensive / Plasma Renin Activity1
Not AvailableCompletedTreatmentSyncope, Vasovagal1
Not AvailableRecruitingTreatmentHypertensive1
Not AvailableRecruitingTreatmentNonvalvular Atrial Fibrillation2
Not AvailableTerminatedTreatmentHypertensive2
Not AvailableTerminatedTreatmentHypertensive / Transplant; Failure, Kidney1
Not AvailableTerminatedTreatmentVentricular Tachycardia (VT)1
Not AvailableUnknown StatusNot AvailableHeart Failure, Unspecified1
Not AvailableUnknown StatusNot AvailableHypertensive1
Not AvailableUnknown StatusNot AvailableMyocardial Ischemia1
Not AvailableUnknown StatusTreatmentFemale Sexual Dysfunction (FSD) / Hypertensive1
Not AvailableUnknown StatusTreatmentHeart Diseases / Heart Valve Disease / Mitral Valve Insufficiency1
Not AvailableWithdrawnNot AvailableCardiac Event Risk1
Not AvailableWithdrawnPreventionMyocardial Ischemia1
Not AvailableWithdrawnTreatmentCentral Aortic Pressure1

Pharmacoeconomics

Manufacturers
  • Novartis pharmaceuticals corp
  • Kv pharmaceutical co
  • Sandoz inc
  • Watson laboratories inc florida
  • Wockhardt ltd
  • Astrazeneca lp
  • Bedford laboratories
  • Hikma farmaceutica (portugal) sa
  • Hospira inc
  • Luitpold pharmaceuticals inc
  • Sagent strides llc
  • Sandoz canada inc
  • Watson laboratories inc
  • Apothecon inc div bristol myers squibb
  • Aurobindo pharma ltd
  • Caraco pharmaceutical laboratories ltd
  • Ipca laboratories ltd
  • Mutual pharmaceutical co inc
  • Mylan pharmaceuticals inc
  • Purepac pharmaceutical co
  • Solco healthcare us llc
  • Teva pharmaceuticals usa inc
  • Teva pharmaceuticals usa
Packagers
Dosage forms
FormRouteStrength
TabletOral25 mg
Tablet, film coatedOral
Kit
TabletOral100 mg
TabletOral50 mg
LiquidIntravenous1 mg
Tablet, extended releaseOral100 mg
Tablet, extended releaseOral200 mg
TabletOral100 mg/1
TabletOral50 mg/1
Tablet, extended releaseOral100 mg/1
Tablet, extended releaseOral200 mg/1
Tablet, extended releaseOral25 mg/1
Tablet, extended releaseOral50 mg/1
Tablet, film coated, extended releaseOral100 mg/1
Tablet, film coated, extended releaseOral200 mg/1
Tablet, film coated, extended releaseOral25 mg/301
Tablet, film coated, extended releaseOral25 mg/1
Tablet, film coated, extended releaseOral50 mg/301
Tablet, film coated, extended releaseOral50 mg/1
Tablet, film coated, extended releaseOral190 mg/1
Tablet, film coated, extended releaseOral23.75 mg/1
Tablet, film coated, extended releaseOral47.5 mg/1
Tablet, film coated, extended releaseOral90 mg/1
InjectionIntravenous5 mg/5mL
Injection, solutionIntravenous1 mg/mL
Injection, solutionIntravenous5 mg/5mL
TabletOral25 mg/1
Tablet, film coatedOral100 mg/1
Tablet, film coatedOral25 mg/1
Tablet, film coatedOral37.5 mg/1
Tablet, film coatedOral50 mg/1
Tablet, film coatedOral75 mg/1
TabletOral
SolutionIntravenous1 mg
Prices
Unit descriptionCostUnit
Metoprolol tartrate powder5.51USD g
Lopressor 5 mg/5 ml ampul3.85USD ml
Lopressor hct 100-25 tablet3.21USD tablet
Toprol XL 200 mg 24 Hour tablet3.08USD tablet
Lopressor HCT 100-50 mg tablet3.06USD tablet
Toprol xl 200 mg tablet2.96USD tablet
Lopressor hct 100-50 tablet2.82USD tablet
Lopressor 100 mg tablet2.75USD tablet
Metoprolol Succinate 200 mg 24 Hour tablet2.62USD tablet
Metoprolol succ er 200 mg tablet2.29USD tablet
Lopressor HCT 100-25 mg tablet2.21USD tablet
Lopressor HCT 50-25 mg tablet2.14USD tablet
Lopressor hct 50-25 tablet2.06USD tablet
Toprol XL 100 mg 24 Hour tablet1.93USD tablet
Toprol xl 100 mg tablet1.86USD tablet
Lopressor 50 mg tablet1.81USD tablet
Metoprolol Succinate 100 mg 24 Hour tablet1.53USD tablet
Metoprolol succ er 100 mg tablet1.44USD tablet
Toprol XL 25 mg 24 Hour tablet1.43USD tablet
Toprol XL 50 mg 24 Hour tablet1.43USD tablet
Lopresor 1 mg/ml1.29USD ml
Toprol xl 25 mg tablet1.24USD tablet
Toprol xl 50 mg tablet1.24USD tablet
Metoprolol Succinate 25 mg 24 Hour tablet1.17USD tablet
Metoprolol Succinate 50 mg 24 Hour tablet1.13USD tablet
Metoprolol succ er 50 mg tablet0.9USD tablet
Metoprolol succ er 25 mg tablet0.87USD tablet
Metoprolol tartrate 100 mg tablet0.8USD tablet
Toprol xl 100 mg tablet sa0.8USD tablet
Lopresor 100 mg Tablet0.61USD tablet
Lopresor Sr 200 mg Sustained-Release Tablet0.61USD tablet
Metoprolol tartrate 50 mg tablet0.56USD tablet
Metoprolol tartrate 25 mg tablet0.34USD tablet
Apo-Metoprolol Sr 200 mg Sustained-Release Tablet0.34USD tablet
Lopresor Sr 100 mg Sustained-Release Tablet0.34USD tablet
Sandoz Metoprolol Sr 200 mg Sustained-Release Tablet0.34USD tablet
Lopresor 50 mg Tablet0.3USD tablet
Apo-Metoprolol (Type L) 100 mg Tablet0.23USD tablet
Apo-Metoprolol 100 mg Tablet0.23USD tablet
Mylan-Metoprolol (Type L) 100 mg Tablet0.23USD tablet
Novo-Metoprol (Fc) 100 mg Tablet0.23USD tablet
Novo-Metoprol 100 mg Tablet0.23USD tablet
Nu-Metop 100 mg Tablet0.23USD tablet
Pms-Metoprolol-L 100 mg Tablet0.23USD tablet
Sandoz Metoprolol (Type L) 100 mg Tablet0.23USD tablet
Apo-Metoprolol Sr 100 mg Sustained-Release Tablet0.19USD tablet
Sandoz Metoprolol Sr 100 mg Sustained-Release Tablet0.19USD tablet
Apo-Metoprolol (Type L) 50 mg Tablet0.13USD tablet
Apo-Metoprolol 50 mg Tablet0.13USD tablet
Mylan-Metoprolol (Type L) 50 mg Tablet0.13USD tablet
Novo-Metoprol (Fc) 50 mg Tablet0.13USD tablet
Novo-Metoprol 50 mg Tablet0.13USD tablet
Nu-Metop 50 mg Tablet0.13USD tablet
Pms-Metoprolol-L 50 mg Tablet0.13USD tablet
Sandoz Metoprolol (Type L) 50 mg Tablet0.13USD tablet
Apo-Metoprolol 25 mg Tablet0.07USD tablet
Pms-Metoprolol-L 25 mg Tablet0.07USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)120 °C (tartarate salt)Not Available
water solubility1.69E+004 mg/L (at 25 °C)MCFARLAND,JW ET AL. (2001)
logP1.88HANSCH,C ET AL. (1995)
Caco2 permeability-4.59ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.402 mg/mLALOGPS
logP1.8ALOGPS
logP1.76ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)14.09ChemAxon
pKa (Strongest Basic)9.67ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area50.72 Å2ChemAxon
Rotatable Bond Count9ChemAxon
Refractivity76.7 m3·mol-1ChemAxon
Polarizability31.9 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9854
Blood Brain Barrier-0.8426
Caco-2 permeable+0.6895
P-glycoprotein substrateSubstrate0.7317
P-glycoprotein inhibitor INon-inhibitor0.8182
P-glycoprotein inhibitor IINon-inhibitor0.8382
Renal organic cation transporterNon-inhibitor0.8418
CYP450 2C9 substrateNon-substrate0.81
CYP450 2D6 substrateSubstrate0.8918
CYP450 3A4 substrateNon-substrate0.6527
CYP450 1A2 substrateNon-inhibitor0.7018
CYP450 2C9 inhibitorNon-inhibitor0.8691
CYP450 2D6 inhibitorNon-inhibitor0.7909
CYP450 2C19 inhibitorNon-inhibitor0.9555
CYP450 3A4 inhibitorNon-inhibitor0.9476
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9897
Ames testNon AMES toxic0.9163
CarcinogenicityNon-carcinogens0.9387
BiodegradationNot ready biodegradable0.8544
Rat acute toxicity1.9180 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8368
hERG inhibition (predictor II)Non-inhibitor0.8202
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
MS/MS Spectrum - Quattro_QQQ 10V, N/ALC-MS/MSsplash10-0v0c-3248359000-0353ef81c3bc6d7fcfd5
MS/MS Spectrum - Quattro_QQQ 25V, N/ALC-MS/MSsplash10-014l-2514911000-b5f7785723f1eaf61e6f
MS/MS Spectrum - Quattro_QQQ 40V, N/ALC-MS/MSsplash10-05ir-1729351100-fb362124379cb4616c5e
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-01b9-9760000000-90ea4861dda115391e26
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-0920000000-b7c75fc96ea4b12a1f40
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-5e678ec3b5c3302abb3c
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0190000000-0ea5b7fc1dda907b176b
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01b9-4940000000-5e4d95fb248589c9af91
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05gi-4900000000-73204756032f7604c22e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05fr-4900000000-597c5d64a09cf1b8f88d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zml-5900000000-ca840796f27bfcb3bd0f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0090000000-9ae9e49826b05fa823f5
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0190000000-cfdea758641b8b5c956e
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-01b9-3940000000-248e03350c5dfe8e1302
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05gi-4900000000-24d3886dc7605253aeb8
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-05gi-4900000000-08c6d3455af24f523db2
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0zmi-5900000000-9b22afca158afbaeb6d1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-0920000000-851dcbef33e79ed22643
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014i-0090000000-61bef9702ed80c36d107
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00xr-9830000000-19e036f6e7d1698645ad
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0ab9-9500000000-a0c8de4980f1bd246201
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-00yi-2900000000-bcd2d1e9320ab40c0cbe
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0kn9-3900000000-a4ead9cd3340096bb484
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014i-0970000000-af48fd7b0dbd70f65107
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-014l-0920000000-91f6498b9bb55aeeacd9
1H NMR Spectrum1D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as tyrosols and derivatives. These are compounds containing a hydroxyethyl group attached to the C4 carbon of a phenol group.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Phenols
Sub Class
Tyrosols and derivatives
Direct Parent
Tyrosols and derivatives
Alternative Parents
Phenoxy compounds / Phenol ethers / Alkyl aryl ethers / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Dialkyl ethers / Organopnictogen compounds / Hydrocarbon derivatives
Substituents
Tyrosol derivative / Phenoxy compound / Phenol ether / Alkyl aryl ether / Monocyclic benzene moiety / 1,2-aminoalcohol / Secondary alcohol / Dialkyl ether / Secondary amine / Secondary aliphatic amine
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
aromatic ether, secondary alcohol, secondary amino compound, propanolamine (CHEBI:6904)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Schafer M, Frischkopf K, Taimor G, Piper HM, Schluter KD: Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat. Am J Physiol Cell Physiol. 2000 Aug;279(2):C495-503. [PubMed:10913016]
  2. Staudt A, Mobini R, Fu M, Grosse Y, Stangl V, Stangl K, Thiele A, Baumann G, Felix SB: beta(1)-Adrenoceptor antibodies induce positive inotropic response in isolated cardiomyocytes. Eur J Pharmacol. 2001 Jul 6;423(2-3):115-9. [PubMed:11448474]
  3. Staudt Y, Mobini R, Fu M, Felix SB, Kuhn JP, Staudt A: Beta1-adrenoceptor antibodies induce apoptosis in adult isolated cardiomyocytes. Eur J Pharmacol. 2003 Apr 11;466(1-2):1-6. [PubMed:12679135]
  4. Johnson JA, Zineh I, Puckett BJ, McGorray SP, Yarandi HN, Pauly DF: Beta 1-adrenergic receptor polymorphisms and antihypertensive response to metoprolol. Clin Pharmacol Ther. 2003 Jul;74(1):44-52. [PubMed:12844134]
  5. Liu J, Liu ZQ, Tan ZR, Chen XP, Wang LS, Zhou G, Zhou HH: Gly389Arg polymorphism of beta1-adrenergic receptor is associated with the cardiovascular response to metoprolol. Clin Pharmacol Ther. 2003 Oct;74(4):372-9. [PubMed:14534524]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Zebrack JS, Munger M, Macgregor J, Lombardi WL, Stoddard GP, Gilbert EM: Beta-receptor selectivity of carvedilol and metoprolol succinate in patients with heart failure (SELECT trial): a randomized dose-ranging trial. Pharmacotherapy. 2009 Aug;29(8):883-90. doi: 10.1592/phco.29.8.883. [PubMed:19637941]

Enzymes

Details
1. Cytochrome P450 2D6
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Belpaire FM, Wijnant P, Temmerman A, Rasmussen BB, Brosen K: The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. Eur J Clin Pharmacol. 1998 May;54(3):261-4. [PubMed:9681670]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and im...
Gene Name
CYP2C19
Uniprot ID
P33261
Uniprot Name
Cytochrome P450 2C19
Molecular Weight
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Quaternary ammonium group transmembrane transporter activity
Specific Function
Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creat...
Gene Name
SLC22A2
Uniprot ID
O15244
Uniprot Name
Solute carrier family 22 member 2
Molecular Weight
62579.99 Da
References
  1. Dudley AJ, Bleasby K, Brown CD: The organic cation transporter OCT2 mediates the uptake of beta-adrenoceptor antagonists across the apical membrane of renal LLC-PK(1) cell monolayers. Br J Pharmacol. 2000 Sep;131(1):71-9. [PubMed:10960071]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100]
  2. Doppenschmitt S, Langguth P, Regardh CG, Andersson TB, Hilgendorf C, Spahn-Langguth H: Characterization of binding properties to human P-glycoprotein: development of a [3H]verapamil radioligand-binding assay. J Pharmacol Exp Ther. 1999 Jan;288(1):348-57. [PubMed:9862789]
  3. Neuhoff S, Ungell AL, Zamora I, Artursson P: pH-dependent bidirectional transport of weakly basic drugs across Caco-2 monolayers: implications for drug-drug interactions. Pharm Res. 2003 Aug;20(8):1141-8. [PubMed:12948010]

Drug created on June 13, 2005 07:24 / Updated on November 19, 2017 20:34